Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2‘-β-Fluoro-2‘,3‘-dideoxyinosine
- 1 January 1996
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 39 (8) , 1619-1625
- https://doi.org/10.1021/jm9509197
Abstract
A series of 6-substituted amino analogs of 9-(2,3-dideoxy-2-fluoro-β-d-threo-pentofuranosyl) purines (F-ddN) has been synthesized and characterized with the objective of finding compounds which might be superior to existing drugs for the treatment of HIV in the central nervous system. These compounds are intended to be more lipophilic than the currently approved anti-HIV drugs for better blood−brain barrier penetration. Subsequent adenosine deaminase (ADA)-catalyzed hydrolysis of these prodrugs in the brain is expected to produce the anti-HIV agent, 9-(2,3-dideoxy-2-fluoro-β-d-threo-pentofuranosyl)hypoxanthine (F-ddI). The new compounds, synthesized from the corresponding 6-chloro analog, include F-ddN which contain methylamino, ethylamino, dimethylamino, hydroxylamino, methoxyamino, benzyloxyamino, hydrazino, and nitro substituents in the 6-position. The 6-nitro analog was isolated as an unexpected product during the preparation of the 6-chloro derivative. Among the analogs with anti-HIV activity, the ethylamino and dimethylamino compounds are ca. 100 times more lipophilic than ddI or F-ddI. As expected, 2‘-fluoro substitution protects the compounds from acid-catalyzed glycosylic cleavage. Only the hydroxylamino and nitro analogs underwent any nonenzymatic hydrolysis at pH 1.0 or 7.4. This reaction, however, results in hydrolysis of the group in the 6-position rather than glycosylic bond cleavage. ADA catalyzes the hydrolysis of the 6-substituents at rates which vary from slightly slower (NO2, 1.7×) to much slower (NHEt, 5000×) than F-ddA. The 6-dimethylamino analog is the only compound which possesses anti-HIV activity (ED50 18 μM) without ADA hydrolysis. With the exception of the two inactive alkoxyamino compounds, the other prodrugs exhibited cellular protection in the HIV-1/PHA-PBM system with IC50 potencies of 7−40 μM.Keywords
This publication has 27 references indexed in Scilit:
- Antiviral therapy for human immunodeficiency virus infectionsClinical Microbiology Reviews, 1995
- Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 2. 6-Halo- and 6-Alkoxy Prodrugs of 2'-.beta.-Fluoro-2',3'-dideoxyinosineJournal of Medicinal Chemistry, 1995
- Enhanced Brain Delivery of an Anti-HIV Nucleoside 2'-F-ara-ddI by Xanthine Oxidase Mediated BiotransformationJournal of Medicinal Chemistry, 1994
- Human immunodeficiency virus type 1 infection of the brainClinical Microbiology Reviews, 1993
- Challenges in the therapy of HIV infectionImmunology Today, 1993
- Pathogenesis and therapy of HIV-1 infection of the central nervous systemAIDS, 1992
- Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugsJournal of Medicinal Chemistry, 1991
- Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIVJournal of Medicinal Chemistry, 1990
- Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacementJournal of Medicinal Chemistry, 1987
- 2',3'-Dideoxy-2'-fluoro-ara-a. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV)Biochemical Pharmacology, 1987